-

Zhangmen Education Inc. Shareholder Alert: Robbins LLP Reminds Investors that Zhangmen Education Inc. (ZME) is Being Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased Zhangmen Education Inc. (NYSE: ZME) American Depository Shares ("ADSs") pursuant to the Company's June 2021 initial public offering ("IPO"). Zhangmen is an education company focused on providing personalized online courses to K-12 students in China.

If you suffered a loss due to Zhangmen Education Inc.'s misconduct, click here.

Zhangmen Education Inc. (ZME) Made False and Misleading Statements in its Offering Materials Supporting its IPO

According to the complaint, Zhangmen filed its Prospectus, which forms part of the Registration Statement for the IPO, with the Securities & Exchange Commission, offering 3.623 million ADSs at $11.50 per ADS. However, defendants failed to disclose that prior to the IPO, China had adopted stringent new regulations aimed at curbing fraud in China's online education market. This sweeping crackdown on the Chinese tutoring industry would effectively ban profit-making in the sector, essentially destroying Zhangmen's business and prospects.

On July 23, 2021, China unveiled its overhaul of the education sector, banning companies that teach school curriculum from making profits, raising capital, or going public. Zhangmen's ADSs trade at less than $1.50 per ADS.

If you purchased Zhangmen Education Inc. (ZME) ADSs pursuant to the Company's June 2021 IPO, you have until January 18, 2022, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Zhangmen Education Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Shareholder Notice: Robbins LLP Informs Investors of the Badger Meter, Inc. Class Action

SAN DIEGO, Calif.--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Badger Meter, Inc. (NYSE: BMI) common stock between April 18, 2024 and April 16, 2026. Badger Meter manufactures and sells water measurement and management products. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that B...

Shareholder Notice: Robbins LLP Informs Investors of the Helen of Troy Limited Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Helen of Troy Limited (NASDAQ: HELE) common stock between April 24, 2024 and October 8, 2025. Helen of Troy markets a variety of consumer goods across several segments.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Helen of...

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder Rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.On January 8, 2026, Beta Bioni...
Back to Newsroom